Penelope A. Bradbury

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Valsamo Anagnostou, Cheryl Ho, Garth Nicholas et al. · Nature Medicine · 2023 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer

Alona Zer, Preet Walia, Leila Khoja et al. · Clinical Lung Cancer · 2018 · 144 citations

Medicine, Hematology, Immunology +16

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

D. Ross Camidge, Jair Bar, Hidehito Horinouchi et al. · Journal of Clinical Oncology · 2024 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Scott A. Laurie, Benjamin Solomon, Lesley Seymour et al. · European Journal of Cancer · 2013 · 109 citations

Medicine, Oncology, Pharmacology +12